about
Gold nanoparticles coated with oligomannosides of HIV-1 glycoprotein gp120 mimic the carbohydrate epitope of antibody 2G12.Gold manno-glyconanoparticles: multivalent systems to block HIV-1 gp120 binding to the lectin DC-SIGN.A new ex vivo method to evaluate the performance of candidate MRI contrast agents: a proof-of-concept study.Glycosystems in nanotechnology: Gold glyconanoparticles as carrier for anti-HIV prodrugsHigh sensitive detection of carbohydrate binding proteins in an ELISA-solid phase assay based on multivalent glyconanoparticles.Multivalent glycoconjugates as anti-pathogenic agentsPreparation and immunogenicity of gold glyco-nanoparticles as antipneumococcal vaccine model.Novel nanoparticle vaccines for Listeriosis.Pregnancy Vaccination with Gold Glyco-Nanoparticles Carrying Listeria monocytogenes Peptides Protects against Listeriosis and Brain- and Cutaneous-Associated Morbidities.Glyconanoparticles: multifunctional nanomaterials for biomedical applications.Carbohydrate-based nanoparticles for potential applications in medicine.Glyconanoparticles as multifunctional and multimodal carbohydrate systems.Influence of ligand presentation density on the molecular recognition of mannose-functionalised glyconanoparticles by bacterial lectin BC2L-A.A solution NMR study of the interactions of oligomannosides and the anti-HIV-1 2G12 antibody reveals distinct binding modes for branched ligands.Gold nanoparticles capped with sulfate-ended ligands as anti-HIV agents.GNP-GAPDH1-22 nanovaccines prevent neonatal listeriosis by blocking microglial apoptosis and bacterial dissemination.A gold glyco-nanoparticle carrying a Listeriolysin O peptide and formulated with Advax™ delta inulin adjuvant induces robust T-cell protection against listeria infection.Synthesis of densely functionalized enantiopure indolizidines by ring-closing metathesis (RCM) of hydroxylamines from carbohydrate-derived nitrones.Low-generation dendrimers with a calixarene core and based on a chiral C(2)-symmetric pyrrolidine as iminosugar mimics.Fabrication of hybrid graphene oxide/polyelectrolyte capsules by means of layer-by-layer assembly on erythrocyte cell templates.Paramagnetic Gd-based gold glyconanoparticles as probes for MRI: tuning relaxivities with sugars.A quantitative study of the intracellular dynamics of fluorescently labelled glyco-gold nanoparticles via fluorescence correlation spectroscopy.STD NMR study of the interactions between antibody 2G12 and synthetic oligomannosides that mimic selected branches of gp120 glycans.Galactofuranose-coated gold nanoparticles elicit a pro-inflammatory response in human monocyte-derived dendritic cells and are recognized by DC-SIGN.Functional Single-Chain Polymer Nanoparticles: Targeting and Imaging Pancreatic Tumors in Vivo.Gold glyconanoparticles coupled to listeriolysin O 91-99 peptide serve as adjuvant therapy against melanoma.Assembling different antennas of the gp120 high mannose-type glycans on gold nanoparticles provides superior binding to the anti-HIV antibody 2G12 than the individual antennas.Loading dendritic cells with gold nanoparticles (GNPs) bearing HIV-peptides and mannosides enhance HIV-specific T cell responses.Multivalent Gold Glycoclusters: High Affinity Molecular Recognition by Bacterial Lectin PA-ILGold Nanoparticles as Carriers for Synthetic Glycoconjugate VaccinesMultimerization of DAB-1 onto Au GNPs affords new potent and selective N-acetylgalactosamine-6-sulfatase (GALNS) inhibitorsDouble addition of grignard reagents to N-glycosyl nitrones: a new tool for the construction of enantiopure azaheterocyclesMultivalent manno-glyconanoparticles inhibit DC-SIGN-mediated HIV-1 trans-infection of human T cellsAntimicrobial Peptide-Loaded Nanoparticles as Inhalation Therapy for Pseudomonas aeruginosa InfectionsPre-clinical development of Listeria-based nanovaccines as immunotherapies for solid tumours: insights from melanomaGold nanoparticles as carriers for a synthetic Streptococcus pneumoniae type 14 conjugate vaccine
P50
Q30401180-78A67EC7-6C55-4523-97BB-AEDCEFAAE5B8Q33493474-506ED533-C48C-41C0-AA94-6F8E9052E209Q33614436-38D3B352-B2F9-4C2C-848A-132C86CFA776Q33829799-0D883ADC-90E2-427B-82BC-04E00E731A4CQ34981074-595FA982-E2E1-4BF4-BF25-36803C271B6BQ35444698-7B54F463-5439-4F7D-95FC-1AF527F144D9Q36202229-923FBE6E-FFF3-4F25-BE72-419F9B0AF1BDQ36256378-C7E120D8-2F4E-40EE-AE52-5157AA284E1EQ37577596-64385CF9-D1AA-4F10-B7B6-631F3564D54BQ37775971-CC800DF8-BDC6-4657-8652-741CE4ACAFF7Q37957320-012E051D-1AC4-4599-91AE-83771985C466Q38071545-D727EB40-7445-4CE3-9F2F-E9BA5145ADC5Q38315565-A4928DED-510A-46A2-9DF6-FA74BCC73DBFQ38337811-8E53DFCD-9A44-428E-8D3E-370BF1D530C5Q39716449-A8863DCD-4277-4126-9E7A-7C36347AA48BQ40048669-2905856B-4514-40EB-817E-D9730FC0B6E4Q41497431-52306ABF-832D-4303-B76C-B16C9D6AB49DQ42083788-9636D9A3-0468-48DE-B41F-1C86CA25A7A8Q42223957-F4524B45-3FF4-4EA5-9654-E0EB30F891C1Q42658379-E782C561-8BA5-4C2B-A5FA-193A47788DD4Q43296968-A541C1C0-1297-4AEB-A76B-5E8EC978CE16Q44973390-1DE98BF8-203F-4008-8197-47F45800609CQ45244200-3C86236C-9F77-4363-8190-5CEDBB6E1082Q46963802-F52649EA-D193-4B15-B0F6-6E9118657698Q51527750-7D650B8D-3234-4FD6-ABDB-3D105ACC87E6Q53159624-A8C3321F-1DC2-46F5-9020-EC00E35F8027Q53241411-75ACD980-75F3-4B06-BF6E-923BC78D8D22Q53831012-D5464ED9-C823-4462-8E07-F008EFED11A2Q57242786-5608AF02-374E-4A68-B644-27B07E6969FCQ57266944-2DBF471C-6154-460C-AE09-2E20A2D61EDCQ58090612-96722F1F-BE9D-47A6-8378-FD4A4AA0F3D7Q81262916-0800E826-873A-4E3C-B298-B9842468E4D7Q84143739-39FB3761-06E5-4EDE-B7F7-85A370F94207Q89939238-DD18EFA5-EECE-439F-93ED-D3861EE2BE17Q91324180-B52C7FE9-E07D-4C1A-BFA6-BBA0ED84B6ACQ95812278-533BC7AD-C1E1-4F41-A2D2-703BEB1A1F0A
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0003-0831-6942
@en
name
Marco Marradi
@ast
Marco Marradi
@en
Marco Marradi
@es
Marco Marradi
@nl
type
label
Marco Marradi
@ast
Marco Marradi
@en
Marco Marradi
@es
Marco Marradi
@nl
prefLabel
Marco Marradi
@ast
Marco Marradi
@en
Marco Marradi
@es
Marco Marradi
@nl
P108
P106
P108
P21
P31
P496
0000-0003-0831-6942